PT1059915E - Amido de ligacaocruzada com alto teor em amilose tendo grupos funcionais como matriz para a libertacao lenta de agentes farmaceuticos - Google Patents

Amido de ligacaocruzada com alto teor em amilose tendo grupos funcionais como matriz para a libertacao lenta de agentes farmaceuticos

Info

Publication number
PT1059915E
PT1059915E PT99936029T PT99936029T PT1059915E PT 1059915 E PT1059915 E PT 1059915E PT 99936029 T PT99936029 T PT 99936029T PT 99936029 T PT99936029 T PT 99936029T PT 1059915 E PT1059915 E PT 1059915E
Authority
PT
Portugal
Prior art keywords
starch
cross
ligacaocruzada
amylostic
matrix
Prior art date
Application number
PT99936029T
Other languages
English (en)
Inventor
Lenaerts Vincent
Chouinard Francois
Mircea A Mateescu
Ispas-Szabo Pompilia
Original Assignee
Pompilia Ispas Szabo
Lenaerts Vincent
Chouinard Francois
Mircea A Mateescu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pompilia Ispas Szabo, Lenaerts Vincent, Chouinard Francois, Mircea A Mateescu filed Critical Pompilia Ispas Szabo
Publication of PT1059915E publication Critical patent/PT1059915E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT99936029T 1998-02-24 1999-02-24 Amido de ligacaocruzada com alto teor em amilose tendo grupos funcionais como matriz para a libertacao lenta de agentes farmaceuticos PT1059915E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/028,385 US6284273B1 (en) 1998-02-24 1998-02-24 Cross-linked high amylose starch resistant to amylase as a matrix for the slow release of biologically active compounds

Publications (1)

Publication Number Publication Date
PT1059915E true PT1059915E (pt) 2005-02-28

Family

ID=21843160

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99936029T PT1059915E (pt) 1998-02-24 1999-02-24 Amido de ligacaocruzada com alto teor em amilose tendo grupos funcionais como matriz para a libertacao lenta de agentes farmaceuticos

Country Status (19)

Country Link
US (2) US6284273B1 (pt)
EP (1) EP1059915B1 (pt)
JP (1) JP2002504508A (pt)
KR (1) KR100713702B1 (pt)
CN (1) CN1298297A (pt)
AT (1) ATE277604T1 (pt)
AU (1) AU755069B2 (pt)
BR (1) BR9908187A (pt)
CA (1) CA2321461C (pt)
CZ (1) CZ301010B6 (pt)
DE (1) DE69920669T2 (pt)
HU (1) HU225045B1 (pt)
IL (1) IL137955A (pt)
NO (1) NO329257B1 (pt)
NZ (1) NZ506437A (pt)
PL (1) PL192468B1 (pt)
PT (1) PT1059915E (pt)
TR (1) TR200003014T2 (pt)
WO (1) WO1999043305A1 (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100389752C (zh) * 1978-04-21 2008-05-28 莱博法姆公司 控释组合物
NZ260408A (en) 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
DE19927688A1 (de) * 1999-06-17 2000-12-21 Gruenenthal Gmbh Mehrschichttablette zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac
US6607748B1 (en) * 2000-06-29 2003-08-19 Vincent Lenaerts Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
US6777000B2 (en) 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
WO2002088331A1 (en) * 2001-05-01 2002-11-07 Universite Du Quebec A Montreal Tridimensional biocompatible support structure for bioartificial organs and uses thereof
US8487002B2 (en) * 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
TWI319713B (en) * 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
DE60322091D1 (de) * 2002-10-25 2008-08-21 Labopharm Inc Zubereitungen mit kontrollierter freisetzung
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
US20080286253A1 (en) * 2004-02-09 2008-11-20 Transfert Plus Societe En Commandite Composition Comprising Polymeric Material And Uses Thereof
CA2491665A1 (fr) * 2004-12-24 2006-06-24 Louis Cartilier Formulation de comprime pour liberation soutenue de principe actif
CA2616204C (en) 2005-09-09 2015-12-01 Labopharm Inc. Sustained drug release composition
ATE540705T1 (de) * 2005-09-21 2012-01-15 Surmodics Inc Überzüge und artikel mit natürlichen biologisch abbaubaren polysacchariden
CA2621597C (en) * 2005-09-21 2014-06-10 Surmodics, Inc. In vivo formed matrices including natural biodegradable polysaccharides and ophthalmic uses thereof
WO2007105719A1 (ja) * 2006-03-14 2007-09-20 National University Corporation NARA Institute of Science and Technology 新規なヘパリン代替材料およびその製造方法
CA2590821A1 (en) * 2007-06-07 2008-12-07 Universite De Montreal High-amylose sodium carboxymethyl starch sustained release excipient and process for preparing the same
CA2678092C (en) * 2007-10-16 2013-07-30 Labopharm Inc. Bilayer composition for the sustained release of acetaminophen and tramadol
CN101161684B (zh) * 2007-11-23 2010-05-19 华南理工大学 交联羧甲基淀粉的红外线合成方法
AU2008338207A1 (en) * 2007-12-17 2009-06-25 Labopharm (Barbados) Limited Misuse preventative, controlled release formulation
MX2010013942A (es) * 2007-12-21 2011-03-25 Akzo Nobel N V Star Polvo de polimero redispersable.
CA2723192A1 (en) 2008-05-07 2009-11-12 Surmodics, Inc. Delivery of nucleic acid complexes from particles
WO2010028489A1 (en) * 2008-09-15 2010-03-18 Labopharm Inc. Starch-based microparticles for the release of agents disposed therein
CA2746888C (en) 2008-12-16 2015-05-12 Labopharm (Barbados) Limited Misuse preventative, controlled release formulation
AR082189A1 (es) 2010-07-06 2012-11-21 Gruenenthal Gmbh Formas de dosificacion gastrorretentivas, procedimiento
US8901092B2 (en) 2010-12-29 2014-12-02 Surmodics, Inc. Functionalized polysaccharides for active agent delivery
WO2012116434A1 (en) * 2011-03-01 2012-09-07 4413261 Canada Inc. (Spencer Canada) Two speed monolithic system for controlled release of drugs
US12109217B2 (en) 2014-02-27 2024-10-08 B-Organic Films Corp. Bioactive agents included in functionalized starch having a single helix V-structure
WO2016100861A1 (en) 2014-12-19 2016-06-23 Baxter International, Inc. Flowable hemostatic composition
CN104784738B (zh) * 2015-04-03 2016-12-07 四川大学 一种天然缓释多效医用海绵
CN106279453B (zh) * 2015-05-28 2019-12-10 易媛 交联的高分子化合物及其制备方法、水凝胶、水基压裂液和用途
CN105536058A (zh) * 2016-01-22 2016-05-04 青岛中腾生物技术有限公司 一种医用淀粉海绵及其制备方法和用途
GB2567493B (en) 2017-10-13 2019-12-18 Altus Formulation Inc Starch-based release modifying excipients and pharmaceutical compositions derived therefrom
CN111072791A (zh) * 2019-12-27 2020-04-28 河南新孚望新材料科技有限公司 一种包膜剂用高直链淀粉的制备方法
JP7125216B1 (ja) 2021-03-31 2022-08-24 長瀬産業株式会社 水溶性ポリマーの製造方法、および吸水性樹脂の製造方法
BR112023019989A2 (pt) * 2021-03-31 2023-11-14 Hayashibara Co Método para produção de polímero solúvel em água e método para produção de resina absorvente de água

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072535A (en) * 1970-12-28 1978-02-07 A. E. Staley Manufacturing Company Precompacted-starch binder-disintegrant-filler material for direct compression tablets and dry dosage capsules
US4369308A (en) * 1981-07-24 1983-01-18 National Starch And Chemical Corporation Low swelling starches as tablet disintegrants
JPH0791240B2 (ja) * 1987-04-01 1995-10-04 株式会社日本触媒 ２−ハロエチルアミンハロゲン化水素酸塩の製造方法
CA2041774C (en) * 1990-11-27 1994-04-19 Mircea A. Mateescu Use of cross-linked amylose as a matrix for the slow release of biologically active compounds
JPH06271704A (ja) * 1993-03-22 1994-09-27 Asahi Chem Ind Co Ltd 水性易燃性組成物
US5616343A (en) * 1993-03-25 1997-04-01 Labopharm, Inc. Cross-linked amylose as a binder/disintegrant in tablets
CN1150218C (zh) * 1994-04-11 2004-05-19 赫希斯特人造丝公司 超吸收性聚合物及其制品
US5830884A (en) * 1995-01-18 1998-11-03 National Starch And Chemical Investment Holding Corporation Pharmaceutical products containing thermally-inhibited starches
US5593503A (en) * 1995-06-07 1997-01-14 National Starch And Chemical Investment Holding Corporation Process for producing amylase resistant granular starch
US5667637A (en) * 1995-11-03 1997-09-16 Weyerhaeuser Company Paper and paper-like products including water insoluble fibrous carboxyalkyl cellulose
CA2173818A1 (fr) * 1996-04-10 1997-10-11 Francois Chouinard Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose
US5879707A (en) * 1996-10-30 1999-03-09 Universite De Montreal Substituted amylose as a matrix for sustained drug release
US5807575A (en) * 1997-02-14 1998-09-15 Rougier Inc. Manufacture of cross-linked amylose useful as a excipient for control release of active compounds

Also Published As

Publication number Publication date
NO329257B1 (no) 2010-09-20
WO1999043305A1 (en) 1999-09-02
AU3242099A (en) 1999-09-15
DE69920669D1 (de) 2004-11-04
JP2002504508A (ja) 2002-02-12
CN1298297A (zh) 2001-06-06
CA2321461A1 (en) 1999-09-02
NO20004208L (no) 2000-08-23
CA2321461C (en) 2008-04-29
NO20004208D0 (no) 2000-08-23
EP1059915B1 (en) 2004-09-29
DE69920669T2 (de) 2005-11-03
PL192468B1 (pl) 2006-10-31
KR20010034531A (ko) 2001-04-25
KR100713702B1 (ko) 2007-05-02
US6419957B1 (en) 2002-07-16
BR9908187A (pt) 2000-10-31
TR200003014T2 (tr) 2001-02-21
HUP0100818A3 (en) 2001-12-28
CZ301010B6 (cs) 2009-10-14
EP1059915A1 (en) 2000-12-20
AU755069B2 (en) 2002-12-05
ATE277604T1 (de) 2004-10-15
PL342596A1 (en) 2001-06-18
IL137955A0 (en) 2001-10-31
HU225045B1 (en) 2006-05-29
NZ506437A (en) 2003-03-28
CZ20003097A3 (en) 2001-06-13
HUP0100818A2 (hu) 2001-08-28
IL137955A (en) 2005-12-18
US6284273B1 (en) 2001-09-04

Similar Documents

Publication Publication Date Title
PT1059915E (pt) Amido de ligacaocruzada com alto teor em amilose tendo grupos funcionais como matriz para a libertacao lenta de agentes farmaceuticos
CY1120313T1 (el) Φαρμακευτικη συνθεση για δερματικη χρηση για να θεραπευεται ψωριαση που περιλαμβανει βιταμινη d και κορτικοστεοειδες
BR9808703A (pt) Composição que fornece medicamento solúvel emágua de dissolução relativamente lenta e usosublingual
BR9910583A (pt) Aminotetralinas n-substituìdas como ligantes para o receptor de neuropeptìdeo y y5 úteis no tratamento de obesidade e outros distúrbios
CY1107586T1 (el) Θepαπεiα για τη δυσκοιλιoτητα
PT1019040E (pt) Inibicao da actividade de p38-quinase por meio de arilureias
BR9809951A (pt) Método para tratamento da obesidade
PL323490A1 (en) Tetralinic compounds exibiting acitity against multgiple-drug refractoriness
MX9205937A (es) Sistema de penetracion incrementada de la piel para surtido topico mejorado de farmacos
CA2041774A1 (en) Use of cross-linked amylose as a matrix for the slow release of biologically active compounds
BR9608041A (pt) Oligossacarídeo sulfatado processo para o tratamento anti-angiogênico anti-metastático e/ou anti-inflamatório de um paciente humano ou outro paciente animal de sangue quente uso de um oligossacarídeo e composição farmacêutica ou veterinária para tratamento anti-angiogênico anti-metastático e/ou anti-inflamatório
ES2177637T3 (es) Medicamentos para el tratamiento de la restenosis, que comprenden polimeros liberadores de oxido nitrico.
BR9714517A (pt) Cicloalquila, lactama, lactona e compostos correlatos, composições farmacêuticas compreendendo os mesmos e processos para inibir liberação de peptìdeo beta-amilóide e/ou sua sìntese por uso de tais compostos
BRPI0417376A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação de receptores de cb1 e sua utilização
TR199900318T2 (xx) IL-8 resept�r antagonistleri.
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
TR199701534T1 (xx) 1,2,4-triazol t�revlerinin, kanserlerin tedavisi i�in bir ila� �retilmesinde kullan�m�.
BR9812774A (pt) Corpos formados para uso como implantes em medicina humana e método para a produção de tais corpos formados
BR0113165A (pt) Derivados de 4-pirimidinamina, composições farmacêuticas e métodos relacionados
ES2136581B1 (es) Uso de derivados del acido-2-hidroxi-4-trifluorometilbenzoico para la preparacion de medicamentos utiles para inhibir el factor de transcripcion nuclear nf-kb.
SE9403905D0 (sv) New formulations
PT1017667E (pt) 2-amino-6-metil-7-acetil-tetralina e composicoes farmaceuticas para a prevencao e para o tratamento terapeutico de patologias inflamatorias e/ou de natureza autoimunitaria
BRPI0414812A (pt) método de inibir a expressão de genes resistentes a múltiplos medicamentos e de inibir a produção de proteìnas resultantes da expressão de tais gene, melhorando assim a efetividade dos agentes quimioterápicos para tratar cánceres
HUP9901935A2 (hu) Gyógyszerek és terápiás szerek és más glikozaminoglikánok (GAG) dózisainak célbajuttatására alkalmas dóziskészlet
BR9808591A (pt) Uso de proteìna de matriz oligomérica de cartilagem para o tratamento de artrite reumatóide.